PMGC Holdings Inc. (ELAB) stock
ELABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/3095% below fair value
$1.48−0.18 (-10.84%)
Close on Nov 17, 2026Market cap $1.32MP/E –Yield –
PMGC EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
PMGC's EPS for the twelve months ending Sep 30, 2024 was -$442.64, down 100.3% year over year. For fiscal 2023 it was -$560.00.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$560.00 | – |
| FY2022 | Dec 31, 2022 | -$264.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.01 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.60 | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.17 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1178.17 | – |
| Q2 FY2025 | Jun 30, 2025 | -$37.98 | – |
| Q1 FY2025 | Mar 31, 2025 | -$248.03 | – |
| Q3 FY2024 | Sep 30, 2024 | -$95.20 | – |
| Q2 FY2024 | Jun 30, 2024 | -$112.00 | – |
| Q1 FY2024 | Mar 31, 2024 | -$113.40 | – |
| Q4 FY2023 | Dec 31, 2023 | -$122.04 | -100.1% |
| Q3 FY2023 | Sep 30, 2023 | -$109.20 | – |
| Q2 FY2023 | Jun 30, 2023 | -$179.20 | – |
| Q1 FY2023 | Mar 31, 2023 | -$155.40 | – |
| Q4 FY2022 | Dec 31, 2022 | $168278.86 | – |
| Q3 FY2022 | Sep 30, 2022 | -$72.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?